Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study.

Antonio Llombart-Cussac,Antonio Anton-Torres,Beatriz Rojas,Raquel Andrés,Noelia Martinez,César A Rodríguez,Sara Marin,Teresa Puértolas,Alejandro Falcón González,María Leonor Fernández-Murga,Carlos Hagen,Manuel Ruiz-Borrego

Cancers（2023）

引用 0|浏览17

暂无评分

摘要

Use of the 21-gene test resulted in an overall 67% reduction in CT recommendation in patients considered candidates for CT. Our findings indicate the substantial potential of the 21-gene test to guide CT recommendations in patients with EBC considered to be at high risk of recurrence based on clinicopathological parameters, regardless of nodal status or treatment setting.

查看译文

关键词

Oncotype DX Breast Recurrence Score®,Recurrence Score® result,adjuvant,breast cancer,chemotherapy,clinical utility

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要